NeoThetis Liquid Biopsy- Comprehensive Panel 222 Genes

What is the NeoThetis Liquid Biopsy Test – Comprehensive Panel of 222 Genes? 

NeoThetis is an innovative, non-invasive liquid biopsy test that helps patients
with cancer select the optimal treatment. It analyzes small amounts of tumor DNA (ctDNA) circulating in the blood, released from both the primary tumor and metastases. The test uses blood as the sample, making it safe and convenient for the patient. This eliminates some of the limitations of traditional tumor biopsies, such as the need for hospitalization after a surgical procedure. 

As part of the extended NeoThetis Liquid Biopsy – Comprehensive Panel, an analysis of 222 genes is performed along with an assessment of MSI¹ and bTMB² biomarkers using next-generation sequencing (NGS). 

¹MSI – Microsatellite Instability  

²bTMB – Blood Tumor Mutational Burden 

 
The price of the test includes a free consultation with an oncologist after receiving the results.   

Who is the NeoThetis Liquid Biopsy – Comprehensive Panel of 222 Genes for? 

The NeoThetis Pan-Cancer Plus test is intended for oncology patients at the initial diagnosis or during disease progression, especially when: 

• The patient's condition or tumor location makes biopsy impossible. 

• Previous biopsy material is unavailable or insufficient. 

• Tumor biopsy is not recommended for clinical reasons. 

• There is a need for rapid therapy selection. 

• Current treatment is ineffective and needs to be changed. 

 

How to Prepare for the NeoThetis Liquid Biopsy – Comprehensive Panel of 222 Genes? 

No special preparation is required. You do not need to fast or stop taking medications. A doctor's referral is not required.  

After purchasing the test, you should go for a blood draw during the opening hours of the selected collection point.  

The test can be performed within 3 months from the purchase date (counting from the date indicated in the order confirmation). 

How is the NeoThetis Liquid Biopsy – Comprehensive Panel of 222 Genes Performed? 

• Purchase the NeoThetis Liquid Biopsy – Comprehensive Panel of 222 Genes – available at any Centrum Medyczne Damiana facility or online. 

• Come for a blood draw during the opening hours of the collection point at one of our facilities.   

• No special preparation is required. You do not need to fast or stop taking medications. A referral is not required. 

• The collected sample is sent for analysis to modern Medicover Genetics laboratories in Cyprus.  

• You will receive the test result within 14 business days from the moment the sample reaches the laboratory. It will be sent to the previously provided email address.   

• FREE ONCOLOGY CONSULTATION – after receiving the report, you can discuss the result with an oncologist within 3 months of receiving the report.   

How Long Does It Take to Get the Results and How to Interpret Them? 

The report (in Polish) will be sent to the provided email address within 14 business days after the sample reaches the laboratory. 

Please note that interpretation of genetic results depends on the patient’s detailed clinical profile. 

After the test, a comprehensive report will be prepared, including detailed interpretation and classification of detected genetic alterations, as well as the latest information on available therapeutic options, allowing for the selection of personalized treatment. 

The test report includes: 

• Assessment of immunotherapy biomarkers MSI and bTMB 
  The microsatellite instability (MSI) status and the tumor mutational burden (bTMB) result are presented together with currently FDA/EMA³-approved immunotherapies. 

• Results of the genetic variant analysis 
  Identified variants of strong, potential, or uncertain significance are reported along with therapies approved by the FDA/EMA or recommended by the NCCN⁴, including:
                Therapies approved for the patient’s indication
                Therapies included in NCCN guidelines
                Variants associated with lack of treatment response 

• Eligibility for clinical trials 
  The report includes currently ongoing clinical trials, expanding therapeutic options for the patient. The results are presented clearly and comprehensively, providing essential information for therapeutic decision-making. 

³FDA – Food and Drug Administration; EMA – European Medicines Agency 

⁴NCCN – National Comprehensive Cancer Network® 

How Can the NeoThetis Liquid Biopsy – Comprehensive Panel of 222 Genes Help You? 

• Performed in a non-invasive manner through a simple blood draw. 

• Enables appropriate therapy selection and reassessment of treatment
  in cases of therapy resistance. 

• Provides information on recommended therapies approved by international oncology societies. 

• Indicates the possibility of participating in available clinical trials. 

• Identifies potential genetic alterations that may occur in distant, inoperable metastases. 

• Enables accurate analysis of genetic alterations and immunotherapy biomarkers MSI and bTMB. 

• Delivers rapid results, allowing for immediate initiation of treatment. 

 

Why Choose the NeoThetis Liquid Biopsy – Comprehensive Panel of 222 Genes? 

NeoThetis Pan-Cancer Plus is a safe, modern alternative to tissue biopsy. The test is performed in certified Medicover Genetics laboratories. 

Find out more and schedule your test! 

The test is conducted by Medicover Genetics (Cyprus) – a laboratory with many years of experience.  

 

Technical Data on the NGS Test: 

An unrivaled process combining patented Targeted Capture Enrichment Technology with next-generation sequencing (NGS) and innovative bioinformatics algorithms ensures precise detection of genetic variants in the NeoThetis Liquid Biopsy – Comprehensive Panel of 222 Genes. 

 

The NeoThetis test detects clinically significant genetic alterations, including: 

• single nucleotide variants (SNVs); 

• insertions and deletions (INDELs); 

• copy number alterations (CNAs); 

• rearrangements; 

The test analyzes the full exons of 222 genes⁵. 

The extended NeoThetis Pan-Cancer Plus panel also assesses immunotherapy biomarkers – microsatellite instability (MSI) and blood tumor mutational burden (bTMB). 

⁵Except for regions containing repeats, sequences with high homology (pseudogenes, segmental duplications), or regions with high/low GC content. 

 

Genetic alterations detected in the NeoThetis Liquid Biopsy – Comprehensive Panel of 222 Genes 

 

SNVs / INDELs – single nucleotide variants / insertions and deletions 

CNAs – copy number alterations  

Rearrangements – rearrangements